Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Average Rating of “Moderate Buy” by Analysts

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $41.40.

A number of equities research analysts have commented on the company. Jefferies Financial Group assumed coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Hemab Therapeutics in a report on Friday. Zacks Research raised Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. The Goldman Sachs Group assumed coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target on the stock. Finally, Evercore assumed coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target on the stock.

Hemab Therapeutics Stock Up 16.8%

Shares of Hemab Therapeutics stock opened at $32.37 on Tuesday. Hemab Therapeutics has a one year low of $23.00 and a one year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Buying and Selling

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were acquired at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the acquisition, the insider directly owned 6,444,637 shares in the company, valued at $160,987,032.26. The trade was a 0.96% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders bought 2,970,541 shares of company stock worth $55,459,603 over the last quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.